100 related articles for article (PubMed ID: 22322558)
1. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice.
Tan Z; Chen P; Schneider N; Glover S; Cui L; Torgue J; Rixe O; Spitz HB; Dong Z
Int J Oncol; 2012 Jun; 40(6):1881-8. PubMed ID: 22322558
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
[TBL] [Abstract][Full Text] [Related]
3. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab.
Meredith R; Torgue J; Shen S; Fisher DR; Banaga E; Bunch P; Morgan D; Fan J; Straughn JM
J Nucl Med; 2014 Oct; 55(10):1636-42. PubMed ID: 25157044
[TBL] [Abstract][Full Text] [Related]
5. Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells.
Zhang KX; Moussavi M; Kim C; Chow E; Chen IS; Fazli L; Jia W; Rennie PS
Cancer Gene Ther; 2009 Nov; 16(11):820-31. PubMed ID: 19373278
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
7. Effects of a human compact anti-ErbB2 antibody on prostate cancer.
Malara AE; Fedele C; Aloj L; Arra C; Laccetti P; D'Alessio G; De Lorenzo C
Oncol Rep; 2012 Jul; 28(1):297-302. PubMed ID: 22505344
[TBL] [Abstract][Full Text] [Related]
8. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: a possible radioimmunotherapy to prostate carcinoma.
Wang HY; Lin WY; Chen MC; Lin T; Chao CH; Hsu FN; Lin E; Huang CY; Luo TY; Lin H
Int J Radiat Biol; 2013 May; 89(5):346-55. PubMed ID: 23294030
[TBL] [Abstract][Full Text] [Related]
10. 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint.
Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
Br J Cancer; 2013 May; 108(10):2013-20. PubMed ID: 23632482
[TBL] [Abstract][Full Text] [Related]
11. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
12. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
13. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
15. Modifications in dynamic contrast-enhanced magnetic resonance imaging parameters after α-particle-emitting ²²⁷Th-trastuzumab therapy of HER2-expressing ovarian cancer xenografts.
Heyerdahl H; Røe K; Brevik EM; Dahle J
Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):153-9. PubMed ID: 23790511
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating macrophages are involved in suppressing growth and metastasis of human prostate cancer cells by INF-beta gene therapy in nude mice.
Zhang F; Lu W; Dong Z
Clin Cancer Res; 2002 Sep; 8(9):2942-51. PubMed ID: 12231540
[TBL] [Abstract][Full Text] [Related]
17. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]